Elevance Health, Inc. (ELV) stock
ELVNYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 21, 2026Score 15/3012% below fair value
$420.07−1.95 (-0.46%)
Close on Oct 30, 2026Market cap $91.10BP/E 18.7Yield –
Earnings
Elevance Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 27, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$50.40B
+0.6% on a year earlier
adjusted diluted EPS, Q3 FY2026
$6.99
$6.03 a year earlier
Latest guidance
Issued
Oct 21, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of Elevance Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 27, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 21, 2026before the open | $50.40B | +0.6% | $6.27 | $6.99 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 15, 2026before the open | $49.80B | +0.8% | $6.71 | $7.45 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 22, 2026before the open | $49.50B | – | $8.00 | $12.58 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 28, 2026before the open | $49.30B | +9.6% | $2.47 | $3.33 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 21, 2025before the open | $50.10B | +12.1% | $5.32 | $6.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 17, 2025before the open | $49.40B | +14.4% | $7.72 | $8.84 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 17, 2025during market hours | – | – | – | – | Filing |
| Q4 FY2024ended Dec 31, 2024 | Jan 23, 2025before the open | $45.00B | +5.9% | $1.81 | $3.84 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 17, 2024before the open | $44.70B | +5.2% | $4.36 | $8.37 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 17, 2024before the open | $43.20B | -0.5% | $9.85 | $10.12 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 18, 2024before the open | $42.30B | +1.0% | $9.59 | $10.64 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 24, 2024before the open | $42.50B | +7.1% | $3.63 | $5.62 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 18, 2023before the open | $42.50B | +7.3% | $5.45 | $8.99 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 19, 2023before the open | $43.40B | +12.7% | $7.79 | $9.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 19, 2023before the open | $41.90B | +10.6% | $8.30 | $9.46 | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 25, 2023before the open | $39.70B | +10.3% | $3.93 | $5.23 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 19, 2022before the open | $39.60B | +11.5% | $6.68 | $7.53 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 20, 2022before the open | $38.50B | – | $6.79 | $8.04 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 22, 2022after the close | $37.90B | – | $7.39 | $8.25 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 26, 2022before the open | $36.00B | – | $4.63 | $5.14 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 20, 2021before the open | $35.50B | – | $6.13 | $6.79 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 21, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | Apr 21, 2021before the open | – | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Jan 27, 2021before the open | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020before the open | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Elevance Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Adjusted Operating Gainnon-GAAP | FY2026 | $6.80B | – | New | Jan 28, 2026 |
| diluted EPSGAAP | FY2026 | $22.00 | – | New | Oct 21, 2026 |
| diluted EPSGAAP | FY2026 | $20.10 | $19.85 | Raised | Jul 15, 2026 |
| adjusted diluted EPSnon-GAAP | FY2026 | $29.00 | – | New | Oct 21, 2026 |
| adjusted diluted EPSnon-GAAP | FY2026 | $27.00 | $26.75 | Raised | Jul 15, 2026 |
| Adjusted Effective Tax Ratenon-GAAP | FY2026 | 22% – 24% | – | Raised | Jan 28, 2026 |
| Adjusted Operating Expense Rationon-GAAP | FY2026 | 10.6% | – | New | Jan 28, 2026 |
| Amortization of Intangible Assets | FY2026 | -$440.00M | – | Raised | Jan 28, 2026 |
| Benefit Expense Ratio | FY2026 | 90.2% | – | New | Jan 28, 2026 |
| Diluted Shares | FY2026 | 219 – 220 | – | New | Jan 28, 2026 |
| Interest Expense | FY2026 | -$1.53B | – | Lowered | Jan 28, 2026 |
| Net Investment income | FY2026 | $1.88B | – | New | Jan 28, 2026 |
| operating cash flowGAAP | FY2026 | $6.50B | – | New | Oct 21, 2026 |
| operating cash flow | FY2026 | $6.00B | $5.50B | Raised | Jul 15, 2026 |
| growth in adjusted diluted earnings per sharenon-GAAP | FY2027 | +12% | – | New | Oct 21, 2026 |
| adjusted EPS growthnon-GAAP | FY2027 | +12% | – | New | Jul 15, 2026 |
Guidance history
Every forecast Elevance Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 21, 2026 | adjusted diluted EPS | FY2026 | $29.00 | New |
| Oct 21, 2026 | growth in adjusted diluted earnings per share | FY2027 | +12% | New |
| Oct 21, 2026 | diluted EPS | FY2026 | $22.00 | New |
| Oct 21, 2026 | operating cash flow | FY2026 | $6.50B | New |
| Jul 15, 2026 | adjusted diluted EPS | FY2026 | $27.00 | Raised |
| Jul 15, 2026 | diluted EPS | FY2026 | $20.10 | Raised |
| Jul 15, 2026 | adjusted EPS growth | FY2027 | +12% | New |
| Jul 15, 2026 | operating cash flow | FY2026 | $6.00B | Raised |
| Apr 22, 2026 | adjusted diluted EPS | FY2026 | $26.75 | Raised |
| Apr 22, 2026 | diluted EPS | FY2026 | $19.85 | Lowered |
| Apr 22, 2026 | operating cash flow | FY2026 | $5.50B | Reaffirmed |
| Jan 28, 2026 | Projected FY 2026 adjusted diluted EPS | FY2026 | $25.50 | New |
| Jan 28, 2026 | Projected FY 2026 GAAP diluted EPS | FY2026 | $22.30 | New |
| Jan 28, 2026 | Adjusted Operating Gain | FY2026 | $6.80B | New |
| Jan 28, 2026 | Adjusted Operating Expense Ratio | FY2026 | 10.6% | New |
| Jan 28, 2026 | Diluted Shares | FY2026 | 219 – 220 | New |
| Jan 28, 2026 | Benefit Expense Ratio | FY2026 | 90.2% | New |
| Jan 28, 2026 | Adjusted Effective Tax Rate | FY2026 | 22% – 24% | Raised |
| Jan 28, 2026 | Net Investment income | FY2026 | $1.88B | New |
| Jan 28, 2026 | Interest Expense | FY2026 | -$1.53B | Lowered |
| Jan 28, 2026 | Amortization of Intangible Assets | FY2026 | -$440.00M | Raised |
| Jan 28, 2026 | Operating Cash Flow | FY2026 | $5.50B | Raised |
| Oct 21, 2025 | Adjusted shareholders' earnings per diluted share | FY2025 | $30.00 | Reaffirmed |
| Oct 21, 2025 | Shareholders' earnings per diluted share | FY2025 | $24.70 | Raised |
| Oct 21, 2025 | benefit expense ratio | FY2025 | 90% | New |
| Jul 17, 2025 | adjusted net income per diluted share | FY2025 | $30.00 | New |
| Jul 17, 2025 | GAAP net income per diluted share | FY2025 | $24.10 | New |
| Jan 23, 2025 | adjusted diluted EPS | FY2025 | $34.15 – $34.85 | New |
| Jan 23, 2025 | GAAP diluted EPS | FY2025 | $30.40 – $31.10 | New |
| Oct 17, 2024 | adjusted net income per diluted share | FY2024 | $33.00 | Lowered |
| Oct 17, 2024 | GAAP net income per diluted share | FY2024 | $26.50 | Lowered |
| Jul 17, 2024 | adjusted diluted net income per share | FY2024 | $37.20 | Reaffirmed |
| Jul 17, 2024 | GAAP net income per diluted share | FY2024 | $34.05 | Reaffirmed |
| Apr 18, 2024 | adjusted diluted EPS | FY2024 | $37.20 | Raised |
| Apr 18, 2024 | diluted EPS | FY2024 | $34.05 | Lowered |
| Jan 24, 2024 | adjusted diluted EPS | FY2024 | $37.10 | New |
| Jan 24, 2024 | GAAP diluted EPS | FY2024 | $34.29 | New |
| Jan 24, 2024 | Adjusted Operating Gain | FY2024 | $10.30B | New |
| Jan 24, 2024 | Diluted Shares | FY2024 | 233 – 234 | New |
| Jan 24, 2024 | Fee-Based | FY2024 | 27.4 – 27.6 | Lowered |
| Jan 24, 2024 | Risk-Based | FY2024 | 18.4 – 19 | Lowered |
| Jan 24, 2024 | Total | FY2024 | 45.8 – 46.6 | Raised |
| Jan 24, 2024 | Benefit Expense Ratio | FY2024 | 87% | New |
| Jan 24, 2024 | Adjusted Operating Expense Ratio | FY2024 | 11.1% | New |
| Jan 24, 2024 | Adjusted Effective Tax Rate | FY2024 | 22% – 24% | Raised |
| Jan 24, 2024 | Operating Cash Flow | FY2024 | $8.10B | New |
| Jan 24, 2024 | Net Investment income | FY2024 | $1.90B | Lowered |
| Jan 24, 2024 | Interest Expense | FY2024 | -$1.10B | Lowered |
| Jan 24, 2024 | Amortization of Intangible Assets | FY2024 | -$450.00M | Raised |
| Jan 24, 2024 | Net Pre-Tax Expense | FY2024 | $350.00M | Raised |
| Oct 18, 2023 | adjusted net income | FY2023 | $33.00 | Raised |
| Oct 18, 2023 | GAAP net income | FY2023 | $26.40 | Lowered |
| Jul 19, 2023 | adjusted net income | FY2023 | $32.85 | Raised |
| Jul 19, 2023 | GAAP net income | FY2023 | $29.09 | Lowered |
| Apr 19, 2023 | adjusted net income | FY2023 | $32.70 | Raised |
| Apr 19, 2023 | GAAP net income | FY2023 | $29.50 | Lowered |
| Jan 25, 2023 | Adjusted EPS | FY2023 | $32.60 | New |
| Jan 25, 2023 | GAAP EPS | FY2023 | $29.80 | New |
| Jan 25, 2023 | Operating Gain | FY2023 | $9.35B | New |
| Jan 25, 2023 | Diluted Shares | FY2023 | 239 – 240 | New |
| Jan 25, 2023 | Fee-Based Medical Enrollment | FY2023 | 27,100 – 27,400 | Raised |
| Jan 25, 2023 | Risk-Based Medical Enrollment | FY2023 | 20,300 – 21,100 | Lowered |
| Jan 25, 2023 | Total Medical Enrollment | FY2023 | 47,400 – 48,500 | Raised |
| Jan 25, 2023 | Benefit Expense Ratio | FY2023 | 87.2% | New |
| Jan 25, 2023 | SG&A Expense Ratio | FY2023 | 11.2% | Lowered |
| Jan 25, 2023 | Effective Tax Rate | FY2023 | 22% – 24% | Raised |
| Jan 25, 2023 | Premium Revenue | FY2023 | $140.00B | New |
| Jan 25, 2023 | Net Investment income | FY2023 | $1.60B | Lowered |
| Jan 25, 2023 | Interest Expense | FY2023 | -$1.00B | Lowered |
| Jan 25, 2023 | Amortization of Intangible Assets | FY2023 | -$869.00M | Raised |
| Jan 25, 2023 | Net Pre-Tax Expense | FY2023 | -$269.00M | Raised |
| Jan 25, 2023 | Operating Cash Flow | FY2023 | $7.60B | Raised |
| Jan 25, 2023 | Operating Revenue | FY2023 | $164.00B | New |
| Oct 19, 2022 | adjusted net income | FY2022 | $28.95 | Raised |
| Oct 19, 2022 | GAAP net income | FY2022 | $25.33 | Raised |
| Jul 20, 2022 | adjusted net income | FY2022 | $28.70 | Raised |
| Jul 20, 2022 | GAAP net income | FY2022 | $25.28 | Lowered |
| Apr 22, 2022 | adjusted net income | FY2022 | $28.40 | Raised |
| Apr 22, 2022 | GAAP net income | FY2022 | $26.43 | Lowered |
| Jan 26, 2022 | adjusted net income | FY2022 | $28.25 | New |
| Jan 26, 2022 | GAAP net income | FY2022 | $26.75 | New |
| Jan 26, 2022 | Operating Gain | FY2022 | $8.40B | New |
| Jan 26, 2022 | Interest expense | FY2022 | $840.00M | Lowered |
| Jan 26, 2022 | Benefit expense ratio | FY2022 | 88% | New |
| Jan 26, 2022 | Risk-based membership | FY2022 | 19.5 – 19.9 | Lowered |
| Jan 26, 2022 | Fee-based membership | FY2022 | 26.1 – 26.3 | Raised |
| Jan 26, 2022 | Share count | FY2022 | 243 – 244 | Raised |
| Jan 26, 2022 | SG&A ratio | FY2022 | 10.8% | Lowered |
| Jan 26, 2022 | Effective tax rate | FY2022 | 22% – 24% | Raised |
| Jan 26, 2022 | premium revenue | FY2022 | $130.00B | New |
| Jan 26, 2022 | Operating cash flow | FY2022 | $6.90B | Lowered |
| Jan 26, 2022 | Investment income | FY2022 | $1.10B | Lowered |
| Jan 26, 2022 | Medical membership | FY2022 | 45.6 – 46.2 | New |
| Jan 26, 2022 | Operating revenue | FY2022 | $152.00B | New |
| Oct 20, 2021 | adjusted net income | FY2021 | $25.85 | New |
| Oct 20, 2021 | GAAP net income | FY2021 | $24.70 | New |
| Oct 20, 2021 | Investment income | FY2021 | $1.20B | Lowered |
| Oct 20, 2021 | Operating cash flow | FY2021 | $6.00B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Elevance Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update